NCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
30 trialsNCT02820857 2025-09-03
BEVANEC
Hospices Civils de Lyon
Phase 2 Completed
NCT00113360 2025-05-01
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03591731 2025-04-01
NIPINEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT04705519 2025-03-14
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Peking University
Phase 2 Completed
NCT03837977 2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2 Completed
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT02318784 2023-12-05
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193531 2023-04-11
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03079440 2022-12-06
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
Phase 2 Completed
NCT03352934 2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00511862 2021-05-13
TheraSphere for the Treatment of Liver Metastases
Boston Scientific Corporation
Phase 2 Completed
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT02113800 2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT04122911 2020-10-26
TENEC
National Cancer Institute, Naples
Phase 2 Completed
NCT03147404 2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2 Completed
NCT02248012 2019-12-19
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Haukeland University Hospital
Phase 2 Completed
NCT02250885 2019-09-17
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Gabrail Cancer Center Research
Phase 2 Completed
NCT02457273 2019-04-03
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT01177007 2017-08-28
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
Phase 2 Completed
NCT01396382 2016-03-29
68Ga
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01121939 2016-02-05
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00607113 2013-07-18
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00004922 2013-06-19
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed
NCT00353015 2012-08-02
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00019786 2012-03-23
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00663429 2011-08-31
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
Callisto Pharmaceuticals
Phase 2 Completed
NCT00953394 2009-08-06
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
University of Turin, Italy
Phase 2 Completed
NCT00388063 2007-12-21
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Callisto Pharmaceuticals
Phase 2 Completed